NCT05695781View on ClinicalTrials.gov

Assessment of the Safety and Efficacy of BRM421 Ophthalmic Solutions in Dry Eye Subjects.

PHASE3CompletedINTERVENTIONAL
Enrollment

740

Participants

Timeline

Start Date

February 27, 2023

Primary Completion Date

December 30, 2023

Study Completion Date

March 30, 2024

Conditions
Dry Eye Disease
Interventions
DRUG

BRM421 Ophthalmic Solution

A topical drop of BRM421 ophthalmic solution.

DRUG

Vehicle

A topical drop of vehicle (minus active) ophthalmic solution.

Trial Locations (1)

02886

Andover Eye Associates, Warwick

Sponsors
All Listed Sponsors
lead

BRIM Biotechnology Inc.

INDUSTRY